Nimbus CEO Talks $4bn Takeda Deal And Capital Cycles
Executive Summary
In December 2022, Nimbus Inc. completed one of the largest single-asset deals in the history of biotech, selling their TYK2 inhibitor program NDI-034858 for an up-front payment of $4bn and up to $2bn in additional milestone payments. What was it like to close a deal of that magnitude? What’s next for Nimbus? The company‘s CEO, Jeb Keiper, reflected on these questions in a recent interview with In Vivo.
You may also be interested in...
Deals Of The Year 2022 Winners Revealed
For In Vivo's 15th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
Takeda Aims At BMS’s Sotyktu In $4bn Deal For Nimbus’s TYK2 Inhibitor
Takeda’s R&D chief Andy Plump said his company has seen data indicating game-changing characteristics for TAK-279 in psoriasis. It plans to bring the candidate into Phase III next year.
Nimbus Nips At BMS’s Heels With Psoriasis Results For TYK2 Inhibitor
Without disclosing data, Nimbus announced positive Phase IIb results for NDI-034858 in psoriasis. The company plans to initiate a Phase III trial next year.